Hypomethylated genes and promoters in this group seem to lose their tumor-suppressing effects (IFITM3 and GLIPR1L2) and perhaps show a reduction in oncogene activity (CAPS2). This evidence concerns the gene GLIPR1L2 and neoplasm.